Efficacy of a spatial repellent for control of malaria in Indonesia:

a cluster-randomized controlled trial

Din Syafruddin[1], Puji BS Asih[1], Ismail Ekoprayitno Rozi[1], Dendi Hadi Permana[1], Anggi Puspa

Nur Hidayati[1], Lepa Syahrani[1], Siti Zubaidah[1], Dian Sidik[2], Michael J. Bangs[3], Claus Bøgh[4],

Fang Liu[5], Evercita C. Eugenio[5], Jared Hendrickson[6], Timothy Burton[7], JK Baird[8], Frank

Collins[7], John P. Grieco[7], Neil F. Lobo[7±] and Nicole L. Achee[7±]*

[1]*Eijkman Institute for Molecular Biology, Jakarta, Indonesia; Department of*
Parasitology, Faculty of Medicine, Universitas Hasanuddin, Makassar,
Indonesia;
[2]*Department of Epidemiology, Faculty of Public Health, Universitas*
Hasanuddin, Makassar, Indonesia
[3]*Public Health and Malaria Control, International SOS, Kuala Kencana,*
Papua Indonesia;
[4]*The Sumba Foundation, Public Health and Malaria Control, Bali,*
Indonesia;
[5]*Department of Applied Mathematics, University of Notre Dame, Indiana;*
[6]*Center for Computer Research, University of Notre Dame, Notre Dame,*
Indiana;
[7]*Department of Biological Sciences, Eck Institute for Global Health,*
University of Notre Dame, Notre Dame, Indiana;
[8]*Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia, and the Centre*
for Tropical Medicine, Nuffield Department of Medicine, University of
Oxford, Oxford, United Kingdom;
24
25 [±]Indicates equal seniority
26
27 *Corresponding author:
28
Nicole L. Achee, PhD
Research Professor
Eck Institute for Global Health
Department of Biological Sciences
239 Galvin Life Science Center
Notre Dame, Indiana 46556
Ph: 574.631.1561
Email: nachee@nd.edu
37

Abstract. A randomized cluster, double-blinded, placebo-controlled trial was conducted to

estimate protective efficacy of a spatial repellent against malaria infection at Sumba, Indonesia.

Following radical cure in 1,332 children aged 6mo-5yrs in 24 clusters, households were given

transfluthrin or placebo passive emanators. Monthly blood screening and biweekly human-

landing mosquito catches (HLC) were performed during 10-months baseline (June 2015 to

March 2016) and a 24-month intervention period (April 2016 to April 2018). Screening detected

164 first-time malaria infections and an accumulative total of 459 infections in 667 subjects in

placebo-control households; and 134 first-time and 253 accumulative total infections among 665

subjects in active intervention households. The 24-cluster protective effect of 27.7% and 31.3%,

for time to first-event and overall (total new) infections, respectively, was not statistically

significant. Purportedly, this due in part to zero to low incidence in some clusters during

intervention undermining the ability to detect an effect. Subgroup analysis of 19 clusters where

at least one malaria infection occurred showed 36.0% and 40.9% (statistically significant at 1-

sided 5% significance level; p=0.0236) protective effect for time to first-event and overall

infections, respectively. Primary entomological analysis of impact proved not statistically

significant, with indoor and outdoor anopheline HLC reduced by 16.4% and 11.3%, respectively.

Among 12 high-risk clusters, a significant impact on infection was detected (about 60%

protective efficacy). While this study suggests protective effects of the intervention, additional

evidence is required to demonstrate that spatial repellents provide a practical and effective means

in reducing malaria transmission.

<u>INTRODUCTION</u>

It has been nearly 75 years since the role of spatial repellency (deterrency or avoidance)

was first described as a potentially beneficial attribute in malaria control, showing chemicals

could effectively disrupt normal mosquito behavior and interrupt contact with humans, thus

preventing disease transmission without actually killing the insect.[1-3] Spatial repellency is used

here as a general term to refer to a range of insect behaviors induced by airborne chemicals that

ultimately result in a reduction in human-vector contact. This can include movement away from

a chemical stimulus, and interference with host detection (attraction-inhibition) and/or feeding

response. [4-7] Spatial repellency action can be measured and distinguished from other chemical

actions, primarily contact irritancy and toxicity, in the laboratory [8, 9] and in semi-field

evaluations.[10, 11] A repellent action drives mosquitoes away from a treated space. Toxics

chemical properties can ultimately kill mosquitoes while irritants rely on brief physical contact

between mosquito (tarsal segments) and a treated surface to promote excitation and avert

prolonged resting. Many compounds can exhibit two or more modes of action and can be

distinguished by the concentration or dose exposure required to achieve a specific outcome. [12]

Currently, the majority of commercial spatial repellent products utilize either low concentrations

of short-duration USEPA registered synthetic pyrethroids (pyrethrin, metofluthrin or most most

recently transfluthrin [13]) or botanical-based compounds.[14, 15]

The World Health Organization (WHO) Vector Control Advisory Group (VCAG) is the

WHO advisory group that assesses evidence on the epidemiological effectiveness of new vector

control interventions and by doing so supports WHO's development of policy recommendations,

including the potential use of spatial repellents as a public health vector control strategy.[16]

Reviewed by VCAG since 2014, the assessment of rigorous epidemiological evidence for

endorsing a policy recommendation of a spatial repellent intervention class remains limited and

deemed insufficient. A malaria prevalence study in China evaluating mosquito coils containing

0.03% transfluthrin demonstrated a 77% reduction in human *Plasmodium falciparum* cases [17]

and the use of coils containing 0.00975% metofluthrin provided 52% protective efficacy (PE)

against new (incident) malaria infections in Indonesia.[18] Although primary outcomes from both

studies were encouraging, neither met the VCAG requirements of rigor due to study design[19]

(non-RCT for China) and/or being underpowered. The importance of a WHO policy for

implementation of spatial repellents in malaria control programs could dramatically increase

investments and efforts by private industry to develop chemicals that operate through different

modes of actions other than acute kill. This would potentially introduce a new generation of

effective active ingredients and product formulations into the disease control/eradication

arsenal.[20, 21] In combination with existing WHO-recommended malaria control interventions,

spatial repellents have the potential to add significant protective benefit, especially where

traditional long-lasting insecticidal nets (LLINs) or indoor residual spraying (IRS) may not be

protective, be unavailable, or are impractical and/or feasible. Control or elimination of malaria in

these circumstances will require innovative approaches, as example spatial repellents providing a

highly protective role against transmission and this may be where spatial repellents may be most

beneficial. [22, 23]

The current claim of a spatial repellent intervention class for public health value is

'deployment of a spatial repellent will prevent human-vector contact to reduce pathogen

transmission'. With this epidemiological primary endpoint in mind, the current large-scale study

aimed to build upon previous epidemiological findings and provide rigorous evidence of a spatial

repellent to provide a sufficient protective effect against malaria infection risk by decreasing the

mean anopheline human landing (biting) rates in endemic communities.

MATERIALS AND METHODS

The study was registered in clinicaltrials.gov (Identifier: NCT02294188) and performed

according to Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) guidelines.

Ethics statement. Ethical review and approval for this study was granted by the Ethics

Committee (EC) of the Faculty of Medicine, Universitas Hasanuddin (Protocol #UH14070385),

the University of Notre Dame (Protocol #14-01-1448) and endorsed by the Eijkman Institute

Research Ethics Committee, Jakarta, Indonesia. Consent was obtained from parents or guardians

of child recruits following EC guidelines. During the consenting process, the study was

described and the consent form read. The consent form detailed the design of the study including

the purpose of collecting and storage of blood samples (towards laboratory-based malaria

diagnosis), descriptions of the study risks, benefits, and procedures of therapeutic radical cure

and follow-up. All households were provided with a signed copy of the consent form after

agreeing to participate in the study. For sentinel households participating in entomological

collections, a script was read that explained the mosquito collection techniques and signed

consent was sought from the head-of-household. No data on individuals was collected during the

entomological collections. Adverse events were captured during participant follow-up and

reported to monitoring authorities in accordance with the approved protocol.

Study site. The study was conducted in Southwest and West Sumba Districts, East Nusa

Tenggara Province, Indonesia (**Figure 1**). The ca. 400,000 residents [24] of the two districts occupy

175 village 'groups' (Desas) and several small-sized towns. Thirteen village groups, with

populations ranging 1,067 to 3,904 (avg. 2,132), served as study locations for the final selection

of the 24 study clusters. Organized bed net campaigns were recently introduced with the last

mass distribution occurring in February-March 2018 across the study area. A mass distribution of

long-lasting insecticidal nets (LLINs) occurred in October-December 2014 in all districts (Olyset

Net® (Olyset Net®, permethrin 2.0% w/w) with > 95% coverage (1 -3 nets per household). A

second round of LLIN mass distribution occurred February-March 2018 (PermaNet® 3.0,

deltamethrin 180mg/m2 + PBO). The last round of focal IRS occurred in 2003 (pyrethroid-

based). The malaria prevalence based on microscopically diagnosed parasitemia drawn from a

random sampling (50% of residents) in 13 villages conducted in 2015, 10 months before the start

of the trial intervention, averaged 15.5% (2.5% to 37.3%) (**Table 1**).

Although very little is known about the malaria vector distribution and bionomics in this

study area, [25] an earlier (August 2007) entomologic survey documented 13 species of

anophelines occurring in West Sumba District: *Anopheles sundaicus* s.l. (Rodenwaldt)*,*

Anopheles subpictus s.l. (Grassi)*, Anopheles barbirostris* s.l. (Van der Wulp)*, Anopheles*

hyrcanus group species (Pallas)*, Anopheles aconitus* (Doenitz)*, Anopheles flavirostris* (Ludlow)*,*

Anopheles annularis (Van der Wulp)*, Anopheles maculatus* (Theobald)*, Anopheles tessellatus*

(Theobald)*, Anopheles vagus* (Doenitz)*, Anopheles leucosphyrus* group species (Doenitz),

Anopheles maculatus s.l. (Theobald) and *Anopheles kochi* (Doenitz). [26, 27] These species vary

spatially in relative abundance in accordance with their respective preferred habitats ranging

from coastal brackish and freshwater marshes and ponds, seasonally productive rice paddies, to

forested hillsides with perennial running streams and small rivers. At the time of the survey,

human-landing collections revealed *An. subpictus* and *An. vagus* the predominant species in the

upland interior locations and *An. sundaicus* the most common species along the coastal plain.

The majority of residents in study villages work in small-holder agriculturalist pursuits, lack

public electricity or articulated water supply, and reside predominately in traditional large,

thatched-roof homes raised ~1m above ground and averaging 80 m^3 in size with bamboo walls

and floor that offer little protection from mosquito entry (**Figure 2**).

Sample size. Previous malaria incidence rates collected in a portion of the study area in coastal

Kodi Subdistrict [18] were used to estimate the likely malaria attack rate in the current study

villages at 0.3 infections/person-year. Sample size determination was based on the hazard rate

comparison in the proportional hazards regression model. [28] The required number of first-time

infections was estimated at 417 to permit detection of a 30% protective effect by the spatial

repellent intervention compared to placebo with 80% power at the type-I error rate, assuming a

between-cluster coefficient of variance (CV) of 30% and a baseline hazard rate of 0.3 per person-

year. With 12 clusters per treatment arm (active or placebo), with 2-month accrual and 22

months follow-up, and an estimated 20% loss-to-follow-up (LTFU) during intervention, a total

of 54 subjects per cluster was required (n=1,296).

Study design. The study was a cluster-randomized, double-blind, placebo-controlled, clinical

trial with a total of 24 clusters divided into 12 clusters per intervention arm. Clusters were based

on housing type, focusing on traditional houses (with or without thatch roofing) (**Figure 2**),

mitigation of potential chemical dispersion 'spillover' effect (i.e., distance between nearest homes

in different clusters ~500 m apart), and logistical considerations (i.e., position of field-based

satellite laboratories). About fifty-four households were recruited within each cluster based on

human sample size requirements. Households from 13 villages were stratified into 24 clusters

before randomization: Gaura (pop. 2,831; houses 432), Kahale (pop. 3,904, houses 253), Karang

Indah (pop. 1,169, houses 139), Manutoghi (pop. 1,067; houses 165), Matakapore (pop. 2,805;

houses 209), Panenggo Ede (pop. 1,271; houses 90), Rada Malando (pop. 1,842; houses 133),

Tana Mete (pop. 2,124; houses 213), Waikarara (pop. 2,709; houses 446), Wailangira (pop.

1,878; houses 226), Waimakaha (pop. 2,334; houses 211), Waimaringi (pop. 2,598; houses 116),

and Weetana (pop. 2,670; houses 275) (**Figure 3**).

Clusters were allocated to receive either active or placebo treatment using a random

number generator (https://www.random.org). The cluster allocation code was made available

from the intervention manufacturer to the Data Safety Monitoring Board (DSMB) for use in

safety assessments. The site database manager assigned a unique identification number to each

household (HIN) and the site intervention administrator coordinated distribution of blinded

active or placebo to enrolled households within each cluster corresponding to the pre-labeled

package code. Unblinded assignments were shared with a site administrator in a sealed envelope

placed in a secure location within the managing center of the research project (Jakarta) for

purposes of emergency unblinding related to adverse and/or serious adverse events. Thus, the

investigators, research team, study subjects, and residents were blinded as to which cluster

received active versus placebo devices until after completion of the study.

The primary endpoint for estimating the protective efficacy (PE) of the spatial repellent

intervention was malaria incidence (time to first infection) among the enrolled sentinel residents

study participants in each of the 24 clusters, i.e., 1,332 subjects in all. These sentinel subjects,

each living in separate households, received a directly observed, presumptive radical cure to

clear them of any standing (patent, sub-patent, or latent) malaria infections. Biweekly blood film

exams were conducted from subjects reporting fever within the previous 48hrs (passive case

detection) with active screening for malaria infection in all subjects occurring every 4 weeks for

the duration of the study.

Enrollment for incidence cohort and radical cure. The average number of children <5 y.o. in

each cluster was 68 (57-79). From individual households in study clusters, one child, aged 6 to

59 months old at time of recruitment, were provided the opportunity to enroll as subjects in the

study. Following informed consent, screening consisted of physical examination by a study

physician and a qualitative NADPH spot test for G6PD deficiency (Trinity Biotech qualitative

G6PD assayTM, ref 345-UV, Trinity Biotech, St. Louis, MO) [29]. Additional to G6PD normal

status, eligibility requirements included a bodyweight 40 kg, hemoglobin > 5mg/dL (Hb201+,

HemoCue AB, Angelholm, Sweden) [30], no severe acute illness/infection on the day of inclusion,

temperature ≤ 38°C, participant acknowledging sleeping in the village > 90% of nights during

any given month, not participating in another clinical trial, and no plans for extended travel

during the study period. A total of 1,451 subjects were presumptively radically treated using a

fixed combination formulation of dihydroartemisinin (DHA)-piperaquine (P) (containing 40 mg

dihydroartemisinin and 320 mg piperaquine; Zhejiang Holley Nanhu, Beijing Holley Cotec)

administered as a weight per dose regimen of 2.25 and 18 mg/kg per dose of dihydroartemisinin

and piperaquine, once daily for 3 days, and primaquine 0.25 mg/kg body weight (PT, Pharos

Tbk, Semarang, Indonesia) for the 14 days immediately before implementing intervention. The

DHA+P combination is currently the first-line antimalarial drug for malaria treatment in

Indonesia.

All subjects were examined for *Plasmodium* spp. infection by expert microscopy, and

polymerase chain reaction (PCR) from matched blood spot samples on filter paper. [31] New

malaria infections among the participants were monitored every 4 weeks using microscopic

examination of Giemsa-stained blood films according to WHO guidelines [32] based on 200 high

magnification (1000x oil-immersion) thick blood film fields. Two certified expert microscopists

independently (blinded) examined slides on-site at project-dedicated field laboratories. PCR

detection of parasites was conducted at the Eijkman Institute for Molecular Biology (EIMB)

central laboratory in Jakarta using PCR techniques for detection of DNA of all four *Plasmodium*

species. [31] A blood sample was defined as 'positive' for inclusion in incidence analyses if

meeting criteria of having two diagnostic outcomes indicating presence of parasite (e.g., 2x

microscopy; 1x microscopy + 1x PCR; or 2x PCR). All positive and 10% randomly selected

negative samples diagnosed at EIMB were re-tested at the University of Notre Dame.

Discordant microscopy and PCR results prompted reexamination of both initial findings.

Participants found malaria infected at point-of-care were immediately treated with DHA+P and

were removed from contributing to further person-time at risk of first-time infection; however,

remained in the study to monitor cumulative incidence for analyses of overall (total new)

infections and estimate number of cases averted.

Intervention. Immediately after completion of radical cure, intervention was simultaneously

initiated in all subject households and non-subject households that consented to receive

intervention. The spatial repellent intervention is a transfluthrin-based passive emanator

241 produced by S.C. Johnson & Son, Inc (SCJ) designed to release a volatile chemical into the air

242 and prevent human–vector contact within the treated space. Transfluthrin is a registered

243 compound commonly found in commercially available mosquito coils globally based on WHO

244 specifications. [33] Emanators (active and placebo) of identical packaging and color were

245 distributed by study personnel every 2 weeks at the individual household application rate of 2

246 units / $9m^2$ according to SCJ specifications. There was a median of 1 room (range 1,9) and 10

247 emanators (range 4,56) per household. Interventions were positioned indoors of houses by

248 hanging on two metal hooks attached to walls. Each position remained static throughout the

249 study. The hooks facilitated stabilization of the interventions so the chemical-treated surface was

250 consistently exposed facing the interior space. Research staff placed, removed and replaced

251 emanators in households at set intervals and recorded attrition during each replacement period to

252 ascertain application rate for use in estimating cluster coverage. Potential adverse health effects

253 (AEs), possibly related to transfluthrin exposure, in subjects and other household members, were

254 reported by the study team during both active and passive blood sampling using a standard

255 survey according to protocol. Investigation of study-related AEs was performed by the on-site

256 study clinician. Severe adverse health events (SAE) were also recorded according to protocol,

257 regardless of possible relationship to intervention. Health clinic data were compiled on a

258 quarterly basis starting in Dec 2017 for DSMB safety assessment of the study population. During

259 the period of the trial, quality control analysis was performed by Ross Laboratories, India on

260 used (after 2-week deployment) and unused (in storage) emanators representing each cluster to

261 check for appropriate amounts of transfluthrin in actives and the absence of transfluthrin in

262 placebos. At the end of follow-up period (April 2018), used, unused and expired emanators

(approximately >2 tons of material) were incinerated by PT. Wahana Pamunah Limba Industri,

Jakarta according to Indonesian regulations.

Entomologic surveys. Adult mosquito diversity and densities were measured using human-

landing catches (HLC) every two weeks from start of baseline through end of follow-up period

in a subset of 12 clusters. Clusters for entomological sampling were hierarchically stratified

based on human landing rate and blindly allocated to treatment arm to ensure a balanced

recruitment (6 clusters in each treatment group). Four neighboring sentinel houses within each of

the 12 clusters were randomly selected for mosquito collections (n=48). Collections were

conducted at sentinel houses for 1 night every 2 weeks from paired active/placebo clusters (e.g.,

3 pairs on Monday night and 3 pairs on Wednesday night) during intervention. All mosquito

collectors were trained and assessed as competent to perform duties required. Each collector

provided informed consent at beginning of the study. Teams of two collectors were assigned per

house, one positioned indoors near the center of the house and one located outside on the house

verandah, approximately ~1 m from the exterior wall. Collectors removed all mosquitoes landing

on their exposed lower legs using a mouth aspirator. Collections were conducted from 1800 to

0600 h for 50 min every hour. Paired collectors rotated the indoor and outdoor position every

hour. Samples were placed into individual holding containers labeled by collection hour interval,

unique house code (linked to blinded treatment code), and collection location (indoor or outside).

Captured mosquitoes were immediately killed by organic compound vapor in the field and

initially identified to species (or species complex) using morphological characters. [34] All

specimens were transported to an on-site study base laboratory upon completion of the 12 h

collection and a random sample of representative anopheline species (up to 30 per cluster and

hour of collection) were dissected for parity and scored as either gravid/parous or nulliparous. [35]

Partial (head-thorax for those dissected for parity) or whole anopheline specimens were placed

singly into individual Eppendorf® 1.5ml vials and stored over silica gel desiccant until further

processing at EIMB, Jakarta, for detection of malaria sporozoites and molecular-based species

identification, [36, 37] where applicable. Mosquito samples were evaluated for *Plasmodium spp.*

infection using polymerase chain reaction (PCR) methodologies [38] to derive corresponding

malaria sporozoite infection rates by parasite species and vector species. Together with time-

adjusted HLC densities (anophelines/person-night), matched sporozoite rates were used to derive

the entomological inoculation rates (EIRs) for each treatment arm. [39] Anopheline species

identification was verified at the University of Notre Dame following previous protocols. [36, 37]

Insecticide susceptibility assays. Permethrin was evaluated using WHO tube and CDC bottle

assay during baseline, intervention and post-intervention periods at the WHO recommended

diagnostic concentration for anophelines 0.75% and CDC recommended dose 21.5µg/ml active

ingredient. Both WHO tube assays and CDC bottle assays were performed on F0 mixed

anopheline species collected as immatures from 13 clusters (23 locations) during baseline,

intervention and 6-mo post-intervention period (ended Oct 2018). Assays were conducted using

non-bloodfed, 3-5 day old females according to established guidelines. [40, 41] After each test

period, all chemical and control specimens were stored individually over silica gel for analysis at

EIMB to confirm species identification and for detection of target-site mechanisms (e.g., *kdr*

mutations) of resistance.

Data management and verification. Data collection was designed around a tablet-based survey

platform linked to a custom-built database and web portal. CommCare (Dimagi Inc, MA) was

selected as the frontend form application, providing critical capabilities, such as: a parent-child

case structure, the ability to store forms when offline, update form versions after deployment,

build forms with complex logic in a web browser, and export form data to other tools. Data was

cleaned according to rules specified in the study protocol to ensure data integrity. Study data

related to participating subjects, participating households, intervention (placement/replacement),

collected mosquitos, and lab analyses was cross checked, identifying missing, incomplete, or

suspect data submissions. These were sent back to the site data manager to be resubmitted or

corrected. Once data correction was complete, data was verified and requested for analyses.

Statistical analyses (S1. Statistical Analyses Plan). Subjects were excluded from analyses when

a subject had no blood sample taken during the intervention period or when a household might

have contributed more than two subjects (rarely) when there was LTFU on the first recruited

subject and a 2nd subject was recruited as a replacement. In the latter case, only the subject with a

longer follow-up period was used based on per-protocol allowing only one subject per household.

The *primary hypothesis* on PE against first-time malaria infection was tested by comparing

the hazard rates of the first-time malaria infection between active and placebo (blank) intervention.

The complementary log-log (cloglog) regression model $\log\left(-\log(1-\theta_{ijt})\right) = \beta_{0t} + x_{ijt}^{t}\beta + z_i$

was.[42-45] θ_{ijt} is the discrete time hazard rate of subject j in cluster *I* at time *t*, x_{ijt} contains visit (as

a categorical predictor), the individual-level (age, gender), household-level (number of doors, open

eaves Y or N, wall type), and cluster-level (baseline incidence rate, cluster population size,

intervention group) covariates, and $z_i \sim N(0,\sigma^2)$ is the cluster-level random effect. PE was

estimated by $(1 - \exp(\beta)) \times 100\%$ with a 90% confidence interval (CI) based on the Wald test,

where $\hat{\beta}$ is the estimated regression coefficient associated with the intervention group, and $\exp(\hat{\beta})$

is the estimated hazard ratio (HR) between active and placebo. The null hypothesis of PE is 0 was

tested by the Wald's test $z = \hat{\beta}/s$, where s is the estimated standard error of $\hat{\beta}$. It was concluded

that active intervention reduces the first-time malaria hazard rate compared to placebo if

$z < z_{0.05} = -1.645$; otherwise, the study would not have enough evidence to suggest that active

intervention reduces the first-time malaria hazard rate compared to placebo at a one-sided

significance level of 5%. The Kaplan-Meier (KM) curves on first-time malaria infection per cluster

was provided for the active and placebo arms, respectively.

340   The statistical method for analyzing *the secondary endpoint* of the overall (total new)

malaria infections detected in study subjects was similar to that used for analyzing the primary

endpoint of the first-time malaria infection except that the above cloglog model has additional term

$z_{j(i)}$, the random effect at the individual level to account for the dependence among multiple

malaria infections per individual. The same set of analyses as the above were performed in a

subgroup analysis in clusters with non-zero baseline incidence rates in clusters used for

entomology data collection.

347   The effects of active intervention on the *secondary entomological endpoints* were

estimated by applying the negative binomial regression model, if applicable. Specifically, *the*

anopheline landing rate (surrogate 'bite' based on HLC and indicator of human-vector contact) is

defined as the number of mosquitos caught during the 12-hr interval overnight**.** The covariates in

the model for analyzing the landing rate includes the fixed effects of intervention group, the

interaction between treatment and location of collection (inside or outside), visit (as categorical),

baseline incidence rate, baseline vector count, cluster population, and random effects for household

nested within cluster and for cluster. The % change in landing rate by intervention was estimated

from the model.   The frequencies and percentages of the captured anophelines were also

summarized by species. The set of the covariates in the model for analyzing *the parity rate* are

similar to the model for analyzing the landing rate, with an additional offset term of the daily

landing rate. Due to the data sparsity issue in the *sporozoite positivity rate* (>99% of the collected

mosquitos were uninfected), no model-based analysis was performed and only summary statistics

are provided for the sporozoite positivity rate data. The *entomological inoculation rate (EIR)* is

defined as the number of infective mosquito bites a person receives per a unit time (typically

annually) and is calculated as $\boxed{\text{EIR} = \text{sporozoite positivity rate} \times \text{human biting rate}}$. The data

sparsity issue experienced by the sporozoite positivity rate data also exists in the EIR data, and

thus only summary statistics are provided on EIR.

<u>RESULTS</u>

Figure 4 summarizes screening, enrollment, and follow-up of the 1,332 subjects of the incidence

density cohorts among the 24 clusters. All subjects completed radical cure and were followed 24

months.

Protective effect against malaria infection among 24 clusters (pre-planned).

Trial outcomes show baseline covariates regarding subject, house construction, population and

baseline malaria incidence between the active and placebo arms were balanced at the individual-,

household-, and cluster-level (**Table 2**). The intervention coverage rate, defined as the proportion

of actually placed emanators over the total number required per household, ranged from 82.2%

to 98.6% by cluster over the entire intervention period, with a mean application rate of 93.2%

and 92.3% for the active and placebo arms, respectively.

There were 134 and 164 first-time infections in active and placebo treatment arms,

respectively, with a hazard ratio of 0.72 (90% CI: 0.43, 1.21) (**Table 3**). A 27.7% decrease in the

first-time malaria hazard risk was estimated using active compared with placebo (90% CI: -

21.3%, 56.9%). The 27.7% PE was not statistically significant at the 5% one-sided significance

level. The estimated PE of active intervention against overall (total) malaria infections (first and

subsequent) was 31.3% (90% CI: -10.8, 57.4%) with a one-sided p-value = 0.098 (**Table 3**).

Investigation of potential shift in parasite species infection frequency (*P. falciparum* vs. *P. vivax*)

between active and placebo will be reported in subsequent publications.

A total of 164 first-time malaria infections occurred during approximately 1032 person-

years at risk in study participants whose households were given placebo, with a calculated

incidence density [46] of 0.159 infections/person-year (**Table 3**, **Figure 5**). In contrast, 134 total

malaria attacks occurred in transfluthrin-active households with approximately 1079 person-

years at risk resulting in a calculated 0.124 infections/person-year. A cumulative 439 malaria

infections (first-time and subsequent) during approximately 1216 person-years at risk were

detected in participants whose households were given placebo, with an incidence density of

0.361 infections/person-year. Contrastingly, 253 total malaria attacks occurred among

participants living in active households with approximately 1216 person-years at risk equaling

0.209 infections/person-year (**Table 3**).

Subgroup analyses of protective effect against malaria infection among non-zero baseline

incidence and entomology clusters (not pre-planned).

Among the 24 clusters, there were five clusters with zero baseline incidence which had zero to

very low incidence rates during intervention. The first subgroup analysis used the 19 clusters

with non-zero baseline incidence rate as the remaining five clusters would have been excluded

from the intervention if baseline analysis had been performed before the randomization.

Excluding these five clusters, the estimated PE for overall (total new) infections in the remaining

subgroup of 19 clusters with non-zero baseline incidence rates was 40.9% (90% CI: 8.61, 61.8%)

resulting in a one-sided p-value of 0.0236 (**Table 3**). The second subgroup analyses included

incidence from the 12 clusters having entomology collection data (i.e., mean anopheline landing

rate), and where the average baseline incidence was ~ 4 folds greater than the other clusters. The

PE using active intervention against time to first-event and overall (total new) malaria infections

in this subgroup was 55.3% and 66%, respectively (**Table 3**). The data indicate the baseline

covariates (subject, house construction, population and baseline malaria incidence) between the

active and placebo arms were balanced at the individual-, household-, and cluster-level in both of

the subgroup analyses (not shown).

Effects on entomological endpoints.

Anopheline landing rates. A total of 26 weeks of HLC were performed within a small subset of

12 clusters during the intervention period. Initial results based on morphological species

identification detected 19 putative malaria vector species showing spatial and temporal variation

across monitored clusters. The most common species attracted to humans included: *Anopheles*

aconitus, *An. annularis*, *An. barbirostris*, *An. flavirostris*, *An. kochi*, *An. maculatus*, *An.*

subpictus, An. sundaicus, An. tessellatus and *An. vagus* (**Table 4**). The cumulative indoor and

outdoor anopheline biting rates are shown in **Figure 6**. There was a numerical reduction in

indoor and outdoor landing density from collections performed at sentinel households containing

active intervention as compared with those assigned to placebos. This difference resulted in

16.4% and 11.3% reduction in anopheline attack rate on collectors positioned indoors and

outdoors, respectively, at sentinel households with active intervention compared with placebo

houses, although this reduction was not statistically significant (**Table 5**).

Sporozoite positivity and Entomological Inoculation Rate (EIR). The frequency of sporozoite

positive anophelines is given in **Table 6.** Only *P. falciparum* and *P. vivax* infections were

detected in captured mosquitoes. During baseline and intervention period, the sporozoite rate was

less than 0.5% for both treatment and placebo arms. Data sparsity regarding comparison of

sporozoite rates precluded formal statistical analyses. The EIR, defined as the number of

infective mosquito bites a person receives per unit time (for example, nightly, monthly or

annually) [39] was <1 bite per year in both treatment arms during baseline and intervention periods.

Parity rate (age-grading). The proportion of sampled females categorized as "older," combining

parous and gravid states (mosquitoes with advanced ovarian follicle development as evidence of

recent blood meal), and those "younger" as nulliparous (non-bloodfed) and recently emerged

were compared between active and placebo treatment for the 12 clusters where entomological

monitoring was conducted. Overall, transfluthrin-active emanators proportionally increased

nulliparity in the sampled anopheline populations compared to placebo for both indoor and

outdoor locations (**Table 7**).

Insecticide resistance. A total of 5,091 adult female anophelines (chemical and control assays)

were evaluated for susceptibility: 700 samples during baseline, 1,805 during intervention and

2,586 post-intervention. *Anopheles vagus* was the most widely distributed and tested anopheline

(56%), followed by *An. sundaicus* (12.6%) and *An. subpictus*, *An. barbirostris*, *An. kochi*, *An.*

aconitus, *An. maculatus*, and *An. tessellatus* (proportionally, all <10%). Baseline, intervention

and post-intervention tests using permethrin (21.5ng/ml) showed 100% knockdown in the CDC

bottle assay between 15-30 min, and 100% 24hr mortality (permethrin 0.75% at 60 min) in the

WHO tube assay. Based on the assumption of predominately pyrethroid-susceptible wild

populations of *Anopheles* spp. present in trial sites, there was no conclusive evidence of

development or increase in phenotypic resistance to pyrethroid class chemicals between pre-and

post-intervention periods. In several clusters during the post-intervention phase, there were

indications of reduced susceptibility in a few *An. barbirostris* populations to permethrin.

Follow-up investigations provided inconsistent results, thus confirmation that these populations

showed low levels of resistance could not be verified.

Adverse Events (AE) and Severe Adverse Events (SAE).

A total of 523 and 144 AEs were reported from non-participants (using government clinic health

records) and the intervention study cohort (collected by the study team), respectively. General

respiratory complaints were most common, followed by general fever. There were 6 total SAEs

reported in the study cohort during follow-up: 2 deaths of unknown cause; 1 case suspected brain

infection; 1 case respiratory infection; 1 case malaria with concomitant bacterial or viral

infection; and 1 case of drowning.

Intervention Quality Control.

A total of 180 emanator samples were analyzed in 2017 taken from different active and placebo

clusters with manufacturing dates ranging from April to November 2016 (15mo - 8mo-old

samples). All sampled placebo interventions were found to be absent for transfluthrin. The

average transfluthrin quantity from all sampled active interventions was within specification

range (55.00 ± 2.75 mg).

DISCUSSION

Malaria remains a significant global public health burden despite recent progress in

reducing disease rates. [47] The primary objective of this large-scale RCT conducted on Sumba

Island, Indonesia was to demonstrate and quantify the protective efficacy (PE) of a passive

emanating spatial repellent intervention (transfluthrin-treated), for reducing malaria incidence

(transmission) in humans. Such evidence of human health impact is a fundamental and essential

requirement in the critical path of development of new vector control intervention classes being

assessed by the WHO VCAG to recommend a global public health policy. [16] Outcomes reported

here are promising for malaria control, despite the study being unable to demonstrate clear,

statistical protective efficacy on primary analysis. The primary per-protocol analyses provides an

estimate of 27% PE against malaria infection, which is near the efficacy of 30% selected in the

power calculations. This effect, however, was not statistically significant with confidence

intervals that include zero. There were 298 first-time infections, in contrast to an expected

number of at least 417 assumed in the sample size calculations, thus resulting on the trial being

underpowered. This study highlights three primary challenges for consideration in future spatial

repellent trials as well for new vector control intervention classes more broadly. Firstly, having

'adaptive' study designs, especially for evaluation in low to moderate malaria transmission

settings and settings with large cluster-to-cluster variance on transmission intensity; second,

defining and identification of the 'key' entomological correlates of protection; and third,

ensuring reliability and feasibility in AE/SAE reporting for accurate safety assessment.

Regarding adaptive study designs, our assumptions for power and sample size

calculations were based on a previous proof-of-concept study that was spatially very near

(border) of the current study area [18] and study villages were selected with the assumption that all

clusters would experience malaria transmission during the intervention period, which,

unfortunately was not the case. Baseline data indicated zero-incidence for five of the 24 selected

study clusters with a 5-folds higher between-cluster variability than assumed in the original

sample size calculation. The 5 clusters with zero baseline incidence (two allocated to receive

active and three allocated to receive placebo) also had either zero or low incidence rates during

intervention and ranked in the top 8 among all 24 clusters in terms of lowness in intervention

incidence (data not shown). In retrospect, a pre-planned analysis of the baseline data would have

allowed adjustment of the study design by filtering out the zero-incidence clusters, or increasing

the study duration (time of follow-up), the number of subjects recruited per cluster, or the

number of clusters to better satisfy requirements of power and capture the necessary number of

outcome events (infections). However, given the updated baseline incidence rate of 0.131 per

person-year and 97.1% CV, to maintain 80% power with the originally assumed 30% PE, 100

clusters per arm with 144 households (HHs; i.e. subjects) would have been required to be

recruited to collect 5,550 first-time malaria events – an unmanageable scale that could not have

been supported due to geographical, logistical and funding constraints. Moreover, increasing

the follow-up time to collect more first-time malaria events would have neither counterbalanced

the large variability nor the longer duration required to collect the additional events due to the

seasonally-influenced low to moderate malaria transmission among clusters. For this reason,

when planning future trials in low or moderate endemic transmission settings, investigators

should consider a greater number of clusters per arm and/or building into the statistical analyses

plan an interim and final analyses of *baseline* incidence with pre-determined study design

adaptations, to include down-selection of clusters with predetermined incidence thresholds. Early

exercises of the impact of a lower than assumed incidence (or greater CV) during study planning

should be explored amongst investigators, industry and funding partners to ensure that the study

area context, intervention manufacturing, program period and/or funding can sufficiently meet

the demands of power requirements if adjustments are to be made once the study

begins. Stakeholders should also discuss supporting and adopting adaptive designs so to allow

decision-making after planned interim analysis of *intervention* data, to either stop the trial for

futility or to continue the trial with adjusted design parameters, such as sample size.[48, 49] Perhaps

just as important in the context of vector control, although RCTs are rated as high-quality

evidence,[50] considerations to RCT alternatives are prudent in the trial planning phase as these

may offer assurances of adequate data rigor while balancing cost and time constraints of

traditional RCTs. [51, 52] Alternatives study designs include large observational studies for

detecting population-level effects using analytical cross-sectional studies, or operational

program-based evidence; the latter perhaps especially for interventions containing an existing

registered chemical active ingredient (i.e., meets human safety thresholds) and where the

intervention is implemented in pilot trials and impact monitored through case reports, as

compared to a contemporaneous control group. [52]

The inclusion of entomological endpoints in the Sumba RCT was, in part, to help

understand and validate the intervention's mode of action for the VCAG claim of a health impact

through a reduction in human-vector contact. Spatial repellent chemicals may cause initial

knockdown and direct kill by exposure to toxic doses at close range to the active ingredient, or a

delayed kill or behavioral avoidance response, through exposure to sub-lethal doses at distances

further away from the stimulus source. Therefore, entomological measurements for detecting

reductions in human landing density with active intervention, and a possible change in

anopheline age structure (parity rate) indicating older populations not surviving as long as in

placebo areas, was built into this study. Additionally, a reduction in sporozoite infection rates

because of lower blood feeding success, and/or an inability to survive the required time interval

(parasite incubation period) to become infective to a susceptible host represent other endpoint

measures of impact on the vector. A causal relationship with one, several or all, of these

endpoints would allow future trials evaluating non-inferiority of a 'second-in-class' spatial

repellent to integrate entomological measures only to predict protective efficacy and provide

assurances of meeting minimum thresholds of acceptance for public health use.

Sporozoite positivity rates and EIR estimates from the current trial were low, with a total

of 42 of 11,650 (0.36%) anophelines tested during baseline (10mo) and 19 of 17,971 (0.11%)

found infected during intervention (24mo). These findings are not unusual or unexpected in low

to moderate malaria transmission settings. [25] As example, the previous Sumba study (using

metofluthrin coils) reported just 15 out of 1,825 (0.82%) HLC anopheline samples sporozoite

infected. [18] The challenges for assessing sporozoite infectivity and using EIR as a measure of

intervention effect in such settings should be factored into study pre-planning to carefully

balance cost of sample processing with potential information gained.

These study findings showed a 16.4% reduction in indoor landing mosquitoes at sentinel

collection houses with active treatment compared to placebo-control. This result differs from the

previous study on Sumba evaluating a metofluthrin-active coil where a significant 32% reduction

in *An. sundaicus* indoor landing rates was found compared to blank coil control.[18] In the previous

and smaller study, *An. sundaicus* was the overwhelmingly predominate human-feeding

anopheline; whereas in the current study this species was relatively uncommon during the

intervention trial. The greater complexity of anopheline diversity in the current study area may

have contributed to the discordant findings between the two studies. Specifically, the range of

ecologies (coastal plains to upland forested hills) varied greatly across the 12 clusters used for

entomology collections in this trial compared to that of the earlier Sumba study where collections

were confined to only 4 adjoining clusters along similar coastal habitats. This variability in

ecology witnessed in the current study resulted in a broad range of species diversity (19 species,

group species captured), each with unique habitat requirements, bionomic and behavioral

characteristics (e.g., biting habits, host preferences). Similar results may occur in future trials that

are conducted in settings with diverse vector populations and/or as cluster size increases thereby

increasing the probability of greater habitat diversity. Other potential reasons for differences in

the effect on anopheline landing rates between the two studies on Sumba include intervention

formulation (i.e., coil vs. passive emanator) as well as species-specific effects by active

ingredients (i.e., metofluthrin vs. transfluthrin). Perhaps just as important as measuring a

reduction in indoor landing rates was the ability to demonstrate an effect on outdoor landing

rates (11% reduction) – on the exposed verandah of houses. Measuring an apparent effect on

outdoor landing is encouraging as many Sumba residents often sleep on the verandah without the

protection of a bed net. Results from further data analyses on effects of this intervention on non-

anopheline populations are forthcoming.

Pertaining to monitoring of insecticide resistance, this labor-intensive activity was

integrated into the study to characterize the wild-type anopheline populations and monitor

changes in susceptibility due to continual exposure of the transfluthrin-active intervention.

Although we are confident in the data presented, there were limitations in sampling from

multiple sites with multiple species during pre-, within, and post-intervention periods to obtain a

clear ("useful") profile of susceptibility background and shift in phenotypic (and molecular)

frequencies. Future trials requiring assessment of insecticide resistance should allow careful

planning and budgeting.

The third 'lesson-learned' from the current study relates to AE and SAE monitoring.

Reports of intervention safety in this study should take into account possible limitations of the

data collection. The DSMB was provided with clinic attendance data from January 2015 to

December 2018, for upper respiratory infection (URI), pneumonia, and malaria, as classified by

month, health center, and village within health center coverage. Although not gathered as part of

the study, the DSMB was keenly interested in these data because of the surprisingly low number

of illnesses/deaths reported from the study population during the entire 24-month intervention

period. For some periods, particularly for malaria infection, the case data were missing or the

health center totals were not available by village. Of the 13 villages represented in the dataset,

all but four comprised clusters (or parts of clusters) from both study intervention arms (i.e., some

allocated to active, and others to placebo); therefore, it was not possible to infer the allocation

status of the corresponding cases. For this reason, the DSMB was unable to make a reliable

assessment of any possible association between active intervention and clinic attendance for

those health conditions reported. The respiratory illnesses in the clinic data are more reflective

of the magnitude of numbers of cases one would expect from this population; however, the

DSMB was again unable to parse them into test and control clusters due to reasons stated above,

and therefore the data was of little use for monitoring purposes. The number of SAEs reported, a

total of only six, is well below the expected in a study population of this size. The WHO

estimates the crude death rate in Indonesia to be approximately 6.2 per thousand per year. [53]

Based on this, for a population of 1,296 children enrolled (the sample size calculation in the

protocol), the probability of having zero deaths in a year is less than one in 1,000. Although open

commemoration of deaths is commonly practiced in the study area, it seems apparent that they

were not completely reported/recorded as SAEs.

Overall, the point to apply for future spatial repellent trials (and perhaps other trials of

new vector control interventions) is to improve the mechanism for capturing adverse events

before the initiation of the study such that all deaths and hospitalizations are reliably reported

and regular monitoring in place for unusual numbers of complaints. If these trials are regarded as

a clinical trial with a placebo that requires comparative AE an SAE data, then almost anything at

this scale could fail simply on the mass of data, however imperfectly collected. Any safety

signal detected would most likely be due to bias in reporting or collection and would have little

to do with the investigational intervention. Trials evaluating a spatial repellent intervention with

a currently registered active ingredient (i.e., a chemical meets regulatory approvals for

acceptable levels of human risk) such as transfluthrin, could focus on a small number of

complaints that might be expected due to inhalation (i.e., volatilization) and develop a

monitoring scheme that collects consistent data across the population. Clinic-based complaints

of respiratory illness such as pneumonia and asthma might be possible, but the variability in their

collection (clinic or survey) will likely be highly dependent on study site infrastructure.

In conclusion, while more evidence will be required to determine whether spatial

repellents can serve as a viable malaria control intervention, both the primary and secondary

results of this Sumba Island trial have generated valuable data and observations that can

contribute to the overall assessment and improvement of testing protocols of a spatial repellent

intervention class. The VCAG has recommended that data from at least one additional trial

evaluating the spatial repellent be generated ,[54] and once available, the panel will be able to

assess the available evidence for judging public health value. If the crude estimate of PE shown

here, near 30%, is replicated in future statistically robust cluster-randomized trials, the

intervention prototype evaluated in this RCT would approximate the benefit associated with

LLINs. [55] Perhaps just as important for endemic countries, the difference in the overall (total

new) infection rate between transfluthrin-active and placebo-control – the number of cases

averted - indicates 361 expected cases per 1000 persons per year (0.361*1000*1) without the

spatial repellent and 152 less cases expected when using the active intervention ((0.361-

0.209)*1000*1). The cost-savings of averting these 152 less cases per 1000 person-years is an

important consideration for health-systems strengthening. These results have encouraged further

and substantial investment to validate spatial repellent efficacy through larger RCTs, including

an investigation of possible diversionary effects on human health (i.e., greater than expected

malaria incidence in households near intervention not receiving product), and evaluation of the

optimal delivery systems for humanitarian assistance use-case scenarios.[56]

Acknowledgments: We extend sincere appreciation to DSMB members: Dennis Shanks, Chris

Drakeley, and Neal Alexander for assurances on data integrity and safety assessments. We also

express our gratitude to fhi360 partners Kathy Bowerman, Ahmed Goolam and Zen Hafy for

trial oversight and monitoring of protocol compliance. We thank the WHO VCAG for their

comments from recurrent project data assessments. We are grateful for the tireless efforts of

Wirda Damanik, study administrator at the Eijkman Institute for Molecular Biology in Jakarta,

and Marianne Kent, Program Coordinator at the University of Notre Dame, for their expert

administrative, logistical, and financial management support of this endeavor. We thank Julie

Neidbalski, Katie Cybulski, Diane Lovin, Joanne Cunningham, Jenna Davidson, and Allison

Hendershot at the University of Notre Dame for their contribution to human blood and mosquito

sample quality control processing as well as David Pettifor of the University of Notre Dame

Center for Research Computing for assisting with central database development and data

verification. We gratefully thank the residents in the study area for their time and patience

participating in this trial. Special gratitude is extended to the Southwest and West Sumba

Districts Health Department for their kind support, the parasitology and entomology teams, local

field workers, data entry clerks, and the numerous local volunteers for their long-serving

dedication to quality of data and meeting the project goals.

Financial support: This study was funded by a substantial award from the Bill & Melinda Gates

Foundation (BMGF) to the University of Notre Dame (Grant# OPP1081737). We express our

gratitude to the Foundation for their long-term generosity and support of spatial repellent product

evaluation and development, especially Kate Aultman, Dan Strickman and Alan Magill. We are

also deeply grateful to SC Johnson for its financial support. The company provided integral

industry and product expertise including the development, manufacturing, delivery and shipment

of the intervention (active and placebo) used in the study. Additionally, SC Johnson provided

expertise in ensuring intervention quality, storage, application and disposal assurances

throughout the trial.

Disclaimer: The contents are the responsibility of the authors.

678   REFERENCES

1. Kennedy JS, 1947. The Excitant and Repellent Effects on Mosquitos of Sub-lethal Contacts
with DDT. *Bull Entomol Res 37:* 593-607.

2. Muirhead-Thomson RC, 1951. Mosquito Behaviour in relation to Malaria Transmission and
Control in the Tropics. London : Edward Arnold & Co., 41, Maddox Street, W.I., 219.

3. De Zulueta J, Cullen JR, Smith A, 1963. Deterrent Effect of Insecticides on Malaria Vectors
. *Nature 200:* 860-862.

4. Dethier VG, Browne BL, Smith CN, 1960. The Designation of Chemicals in Terms of the
Responses They Elicit from Insects. *J Econ Entomol 53:* 134-136.

5. Miller JR, Siegert PY, Amimo FA, Walker ED, 2009. Designation of Chemicals in Terms of
the Locomotor Responses they Elicit from Insects: an Update of Dethier et al. (1960). *J Econ
Entomol 102:* 2056-2060.

6. Roberts DR, Alecrim WD, Hshieh P, Grieco JP, Bangs M, Andre RG, Chareonviriphap T,
2000. A Probability Model of Vector Behavior: Effects of DDT Repellency, Irritancy, and
Toxicity in Malaria Control. *J Vector Ecol 25:* 48-61.

7. World Health Organization, WHO Pesticide Evaluation Scheme, 2013. Guidelines for
Efficacy Testing of Spatial Repellents.

8. Grieco JP, Achee NL, Sardelis MR, Chauhan KR, Roberts DR, 2005. A Novel High-
Throughput Screening System to Evaluate the Behavioral Response of Adult Mosquitoes to
Chemicals. *J Am Mosq Control Assoc 21:* 404-411.

9. Achee NL, Sardelis MR, Dusfour I, Chauhan KR, Grieco JP, 2009. Characterization of Spatial
Repellent, Contact Irritant, and Toxicant Chemical Actions of Standard Vector Control
Compounds. *J Am Mosq Control Assoc 25:* 156-167.

10. Ogoma SB, Ngonyani H, Simfukwe ET, Mseka A, Moore J, Maia MF, Moore SJ, Lorenz
LM, 2014. The Mode of Action of Spatial Repellents and Their Impact on Vectorial Capacity of
Anopheles gambiae sensu stricto. *PLoS ONE 9:* e110433.

11. Ogoma SB, et al, 2014. An Experimental Hut Study to Quantify the Effect of DDT and
Airborne Pyrethroids on Entomological Parameters of Malaria Transmission. *Malar J 13:* 131.

12. Grieco JP, Achee NL, Chareonviriyaphap T, Suwonkerd W, Chauhan K, Sardelis MR,
Roberts DR, 2007. A New Classification System for the Actions of IRS Chemicals Traditionally
Used For Malaria Control. *PLoS One 2:* e716.

13. U.S EPA Office of Pesticide Programs, 2018. Conventional New Chemical Registration
Decisions - Completed FY 2018.

14. Norris E, Coats J, 2017. Current and Future Repellent Technologies: The Potential of Spatial
Repellents and Their Place in Mosquito-Borne Disease Control. *International Journal of*
Environmental Research and Public Health 14: 124.

15. Debboun M, Frances SP, Strickman D, Frances SP, Strickman D, 2006. Insect Repellents:
Principles, Methods, and Uses. CRC Press, 495.

16. WHO, 2017. The Evaluation Process for Vector Control Products. *WHO*.

17. Hill N, Zhou HN, Wang P, Guo X, Carneiro I, Moore SJ, 2014. A Household Randomized,
Controlled Trial of the Efficacy of 0.03% Transfluthrin Coils Alone and in Combination with
Long-Lasting Insecticidal Nets on the Incidence of *Plasmodium falciparum* and *Plasmodium*
vivax Malaria in Western Yunnan Province, China. *Malar J 13:* 208.

18. Syafruddin D, et al, 2014. Impact of a Spatial Repellent on Malaria Incidence in Two
Villages in Sumba, Indonesia. *Am J Trop Med Hyg 91:* 1079-1087.

19. WHO-Department of Control of Neglected Tropical Diseases, 2017. How to Design Vector
Control Efficacy Trials. Guidance on Phase III Vector Control Field Trial Design. *WHO* 62.

20. Ogoma SB, Moore SJ, Maia MF, 2012. A Systematic Review of Mosquito Coils and Passive
Emanators: Defining Recommendations for Spatial Repellency Testing Methodologies. *Parasit*
Vectors 5: 287.

21. Achee NL, Grieco JP, 2012. Is It Time to Formally Recognize Spatial Repellency for Disease
Prevention? *Outlooks on Pest Management 23:* 283-286.

22. Achee NL, et al, 2012. Spatial Repellents: from Discovery and Development to Evidence-
Based Validation. *Malar J 11:* 164.

23. Hemingway J, Shretta R, Wells TNC, Bell D, Djimdé AA, Achee N, Qi G, 2016. Tools and
Strategies for Malaria Control and Elimination: What Do We Need to Achieve a Grand
Convergence in Malaria? *PLoS Biol 14:* e1002380.

24. Badan Pusat Statistik, 2010 Population Census - Indonesia. . Available from:
http://sp2010.bps.go.id/. Accessed Jul 10, 2019.

25. Elyazar IRF, Sinka ME, Gething PW, Tarmidzi SN, Surya A, Kusriastuti R, Winarno n,
Baird JK, Hay SI, Bangs MJ, 2013. The Distribution and Bionomics of Anopheles Malaria
Vector Mosquitoes in Indonesia. Anonymous Advances in Parasitology. , 173-266.

26. Barbara KA, Sukowati S, Rusmiarto S, Susapto D, Bangs MJ, Kinzer MH, 2011. Survey of
Anopheles Mosquitoes (Diptera:Culicidae) in West Sumba District, Indonesia. *Southeast Asian J*
Trop Med Public Health 42: 71-82.

27. Asih PBS, Dewi RM, Tuti S, Sadikin M, Sumarto W, Sinaga B, van der Ven, Andre J. A. M.,
Sauerwein RW, Syafruddin D, 2009. Efficacy of Artemisinin-Based Combination Therapy for
Treatment of Persons with Uncomplicated *Plasmodium falciparum* Malaria in West Sumba
District, East Nusa Tenggara Province, Indonesia, and Genotypic Profiles of the Parasite. *Am J*
Trop Med Hyg 80: 914-918.

28. Lievens M, Aponte JJ, Williamson J, Mmbando B, Mohamed A, Bejon P, Leach A, 2011.
Statistical Methodology for the Evaluation of Vaccine Efficacy in a Phase III Multi-centre Trial
of the RTS, S/AS01 Malaria Vaccine in African Children. *Malar J 10:* 222.

29. Kim HC, et al, 2011. Japanese Encephalitis Virus in Culicine mosquitoes (Diptera:
Culicidae) Collected at Daeseongdong, a Village in the Demilitarized Zone of the Republic of
Korea. *J Med Entomol 48:* 1250-1256.

30. Bernard Nkrumah, Samuel Blay Nguah, Nimako Sarpong, Denise Dekker, Ali Idriss, Juergen
May and Yaw Adu-Sarkodie, 2011. Hemoglobin Estimation by the HemoCue® Portable
Hemoglobin Photometer in a Resource Poor Setting. *BMC Clinical Pathology 11:*.

31. Echeverry DF, et al, 2016. Human Malaria Diagnosis Using a Single-step Direct-PCR Based
on the *Plasmodium* cytochrome oxidase III gene. *Malar J 15:* 128.

32. World Health Organization & UNICEF/UNDP/World Bank/WHO Special Programme for
Research and Training in Tropical Diseases, 2015. Microscopy for the Detection, Identification
and Quantification of Malaria Parasites on Stained Thick and Thin Blood Films in Research
Settings. *World Health Organization* 33.

33. WHO Specifications and Evaluations for Public Health Pesticides, 2016. Transfluthrin.
World Health Organization.

34. O'Connors CT, Soepanto A, 1979. Kunci kunci bergambar untuk Anopheles betina dari
Indonesia. Translated and revised by Atmosoedjono S, Bangs, MJ, 1989. Illustrated key to the
Anopheles of Indonesia. 1989. 1-40.

35. Detinova TS, 1962. Age-grouping Methods in Diptera of Medical Importance with Special
Reference to some Vectors of Malaria. *Monogr Ser World Health Organ 47:* 13-191.

36. Lobo NF, et al, 2015. Unexpected Diversity of *Anopheles* Species in Eastern Zambia:
Implications for Evaluating Vector Behavior and Interventions using Molecular Tools. *Sci Rep*
5: 17952.

37. St Laurent B, et al, 2016. Behaviour and Molecular Identification of *Anopheles* Malaria
Vectors in Jayapura District, Papua Province, Indonesia. *Malar J 15:* 192.

38. Echeverry DF, et al, 2017. Fast and Robust Single PCR for *Plasmodium* sporozoite Detection
in Mosquitoes using the Cytochrome Oxidase I Gene. *Malar J 16:* 230.

39. Beier JC, 2002. Vector Incrimination and Entomological Inoculation Rates. *Methods Mol*
Med 72: 3-11.

40. WHO, 2018. Test Procedures for Insecticide Resistance Monitoring in Malaria Vector
Mosquitoes (Second edition).

41. Center for Disease Control and Prevention, Guideline for Evaluating Insecticide Resistance
in Vectors Using the CDC Bottle Bioassay.

42. John D. Kalbfleisch, Ross L. Prentice, 2002. The Statistical Analysis of Failure Time Data.
John Wiley and Sons, 462.

43. Paul D. Allison, 1982. Discrete-Time Methods for the Analysis of Event Histories.
Sociological Methodology 13: 61-98.

44. David Collett, 2002. Modelling Binary Data. Chapman and Hall/CRC, 408.

45. Redmond, C. and Colton, T., ed., 2001. Biostatistics in Clinical Trials. John Wiley & Sons.

46. Baird JK, Bangs MJ, Maguire JD, Barcus MJ, 2002. Epidemiological Measures of Risk of
Malaria. *Methods Mol Med 72:* 13-22.

47. World Health Organization, 2018. World Malaria Report 2018. *WHO*.

48. Brown CH, Ten Have TR, Jo B, Dagne G, Wyman PA, Muthén B, Gibbons RD, 2009.
Adaptive Designs for Randomized Trials in Public Health. *Annu Rev Public Health 30:* 1-25.

49. Shein-Chung Chow MC, 2011. Adaptive Design Methods in Clinical Trials. Chapman and
Hall/CRC Biostatistics Series, 375.

50. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ,
2008. GRADE: an Emerging Consensus on Rating Quality of Evidence and Strength of
Recommendations. *BMJ 336:* 924-926.

51. Frieden TR, 2017. Evidence for Health Decision Making - Beyond Randomized, Controlled
Trials. *N Engl J Med 377:* 465-475.

52. Wilson AL, Boelaert M, Kleinschmidt I, Pinder M, Scott TW, Tusting LS, Lindsay SW,
2015. Evidence-based Vector Control? Improving the Quality of Vector Control Trials. *Trends*
Parasitol 31: 380-390.

53. WHO-Global Health Observatory Data Repository, 2015. Crude Birth and Death Rate
Data by Country. . Available from: http://apps.who.int/gho/data/view.main.CBDR2040.
Accessed 07/08/2019.

54. VCAG, Vector Control Advisory Group. . Available from: http://www.who.int/vector-
control/vcag/en/. Accessed Jul 10, 2019.

55. Lengeler C, 2004. Insecticide-treated Bed Nets and Curtains for Preventing Malaria.
Cochrane Database Syst Rev CD000363.

56. Unitaid, Innovative Repellents for Disease-carrying Mosquitoes. . Available from:
https://unitaid.org/project/innovative-repellents-for-disease-carrying-mosquitoes/. Accessed Jul
10, 2019.

FIGURES

Figure 1. Study site areas in Southwest and West Sumba districts located in Kodi, Kodi Bangedo and Lamboya sub-districts of Sumba Island, Nusa Tenggara Timur Province (eastern Lesser Sunda islands), Indonesia (map not to scale).

Figure 2. Traditional Sumba house structure (A) raised ~1m above ground and averaging 80 m³ in size with thatch roof, bamboo floors and walls (B), that offer little protection from mosquito entry.

Figure 3. Location of 24 study clusters. Clusters were selected for enrolling the incidence cohort, each consisted of ca. 100 households with an average distance of 500m between clusters. A total of 48 sentinel houses from 12 clusters were selected for routine entomological collections.

Figure 4. Flowchart of enrollment of study volunteers. A total of 1,684 subjects were screened for G6PD deficiency and 1,488 consented to be enrolled and provided radical cure for active or presumptive malaria of which 1,451 completed the treatment and subsequently followed-up for 24 months during intervention.

Figure 5: Cumulative incidence of first-time malaria infection by cluster (12 per treatment arm).

Figure 6. Cumulative biweekly indoor (A) and outdoor (B) anopheline landing rates by treatment group (averaged over 20 to 24 households per treatment group).

TABLES

Table 1. Parasitological prevalence data of the 13 study villages on Sumba Island conducted in 10 months before cluster randomization.

Village	Number of samples	Number of malaria infections	Slide Positive Rate (%)
Matakapore	806	110	13.65
Manutoghi	622	217	34.88
Waimakaha	621	149	23.99
Wailangira	857	52	6.07
Waikarara	1,420	63	4.44
Panenggo Ede	610	15	2.46
Waimaringi	649	67	10.32
Tana Mete	810	81	10.00
Kahale	903	202	22.37
Rada Malando	402	150	37.31
Karang Indah	523	195	37.28
Gaura	1,297	165	12.70
Weetana	1,129	163	14.40

Table 2. Summary baseline covariates by treatment arm for the primary analysis.

Individual level		
	SR (n = 665)	**Placebo (n = 667)**
Age in months (mean $\pm$ SD, (min, max))	34.0 $\pm$ 15.1 (6, 59)	34.2 $\pm$ 14.8 (6, 59)
Gender (% of male subjects)	54.1%	51.1%
Household level		
	SR (n = 665)	**Placebo (n = 667)**
House wall type (Wood %)	91.6%	94.0%
Open eaves (Yes %)	98.0%	99.6%
# of doors (mean $\pm$ SD, (min, max))	2.06 $\pm$ 0.38 (1, 4)	2.06 $\pm$ 0.30 (0, 4)
Cluster level		
	SR (n = 12)	**Placebo (n = 12)**
Cluster population (mean $\pm$ SD, (min, max))	694.3 $\pm$ 59.2 (624, 820)	730.8 $\pm$ 129.0 (616,1117)
Baseline incidence rate per person-year (mean $\pm$ SD, (min, max))	0.096 $\pm$ 0.115 (0, 0.426)	0.089 $\pm$ 0.088 (0, 0.265)
Baseline overall (total new) infection incidence per person-year (mean $\pm$ SD, (min, max))	0.094 $\pm$ 0.111 (0, 0.412)	0.089 $\pm$ 0.087 (0, 0.261)

Table 3. Summary first-time and overall (total) malaria incidence.

	First-time infection			Overall (total new) infection		
	All clusters	Subgroup 1[#]	Subgroup 2[#]	All clusters	Subgroup 1[#]	Subgroup 2[#]
	SR : Placebo					
Cluster	12:12	10:9	6:6	12:12	10:9	6:6
Households	665: 667	557: 500	335:335	665: 667	557: 500	335 : 335
Malaria infections	134 : 164	130 : 158	93 : 140	253 : 439	249 : 433	196 : 408
person years	1079 : 1032	873 : 722	506 : 444	1216 :1216	1015 : 909	609 : 607
Incidence rate (ppy)	0.124 : 0.159	0.149 : 0.219	0.184 : 0.315	0.208 : 0.361	0.245 : 0.476	0.322 : 0.672
Hazard ratio (90% CI)	0.723 (0.431,1.213)	0.64 (0.299, 1.367)	0.447 (0.302, 0.664)	0.687 (0.426,1.108)	0.591 (0.382, 0.914)	0.344 (0.233, 0.508)
PE (%) (90% CI)	27.7 (-21.3, 56.9)	33.3 (-7.8, 58.7)	55.3 (33.6, 69.9)	31.3 (-10.8, 57.4)	40.9 (8.61, 61.8)	65.6 (49.2, 76.7)
1-sided p-value	0.151	0.083	0.0004	0.098	0.0236	<0.0001

[#] Subgroup 1: clusters with non-zero baseline incidence
[#] Subgroup 2: clusters with entomology data

Table 4. Frequency (percentage) of anopheline species captured during sentinel human-landing catch (HLC) based on adult morphological character identification*.

Anophelines	Baseline Period				Intervention Period			
	Indoor		Outdoor		Indoor		Outdoor	
	SR	Placebo	SR	Placebo	SR	Placebo	SR	Placebo
Total	**2243 (100%)**	**3327 (100%)**	**2896 (100%)**	**3462 (100%)**	**3883 (100%)**	**4897 (100%)**	**4372 (100%)**	**4834 (100%)**
An. aconitus	467 (20.82%)	80 (2.40%)	768 (26.52%)	78 (2.25%)	2015 (51.89%)	173 (3.53%)	2249 (51.44%)	162 (3.35%)
An. annularis	55 (2.45%)	633 (19.03%)	70 (2.42%)	567 (16.38%)	82 (2.11%)	544 (11.11%)	99 (2.26%)	493 (10.20%)
An. balabacensis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (0.05%)	1 (0.02%)	0 (0%)	0 (0%)
An. barbirostris	41 (1.83%)	148 (4.45%)	49 (1.69%)	132 (3.81%)	62 (1.60%)	360 (7.35%)	56 (1.28%)	322 (6.66%)
An. barbumbrosus	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.03%)	0 (0%)	0 (0%)	3 (0.06%)
An. flavirostris	355 (15.83%)	417 (12.53%)	523 (18.06%)	504 (14.56%)	757 (19.50%)	430 (8.78%)	1001 (22.90%)	482 (9.97%)
An. indefinitus	0 (0%)	1 (0.03%)	0 (0%)	1 (0.03%)	2 (0.05%)	12 (0.25%)	4 (0.09%)	20 (0.41%)
An. karwari	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.02%)	0 (0%)
An. kochi	47 (2.10%)	501 (15.06%)	36 (1.24%)	392 (11.32%)	90 (2.32%)	803 (16.40%)	88 (4.71%)	836 (17.29%)
Leucosphyrus Group	0 (0%)	1 (0.03%)	0 (0%)	0 (0%)	2 (0.05%)	16 (1.61%)	1 (0.02%)	26 (0.54%)
An. maculatus	61 (2.72%)	88 (2.65%)	95 (3.28%)	88 (2.54%)	209 (5.38%)	79 (1.61%)	206 (4.71%)	94 (1.94%)
An. montanus	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.03%)	0 (0%)	1 (0.02%)	0 (0%)
An. parangensis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.02%)	0 (0%)	0 (0%)
Hyrcanus Group	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	4 (0.08%)	0 (0%)	2 (0.04%)
An. subpictus	15 (0.67%)	7 (0.21%)	13 (0.45%)	15 (0.43%)	3 (0.08%)	105 (2.14%)	10 (0.23%)	85 (1.76%)
An. sundaicus	1001 (44.63%)	401 (12.05%)	1154 (39.85%)	562 (16.23%)	136 (3.50%)	61 (1.25%)	128 (2.93%)	62 (1.28%)
An. tessellatus	94 (4.19%)	317 (9.53%)	89 (3.07%)	295 (8.52%)	205 (5.28%)	1246 (25.44%)	192 (4.39%)	1215 (25.13%)
An. umbrosus	0 (0%)	0 (0%)	1 (0.03%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
An. vagus	107 (4.77%)	733 (22.03%)	98 (3.38%)	828 (23.92%)	315 (8.11%)	1061 (21.67%)	334 (7.64%)	1031 (21.33%)
Unknown	0 (0%)	0 (0%)	0 (0%/)	0 (0%)	1 (0.03%)	1 (0.02%)	2 (0.046%)	1 (0.02%)

*Misidentification possible depending on physical condition of specimen, molecular methods required to separate out some members in species groups and complexes.

Table 5: Intervention effect on anopheline mosquito landing rates by collection location[1].

Location[1]	Active (mean $\pm$ SD)	Placebo (mean $\pm$ SD)	% Change (95% CI) Active vs. Placebo	p-value
Indoor	3.14 $\pm$ 5.84	3.97 $\pm$ 8.73	-16.4 (-75.2, 182.7)	0.774
Outdoor	3.54 $\pm$ 7.13	3.93 $\pm$ 8.64	-11.3 (-73.7, 199.4)	0.847

[1]Position at each HLC sentinel house where sample was captured (indoor = near center of house; outdoor = on verandah ~1m from edge of exterior wall.

Table 6. Frequency of anopheline (all species) sporozoite positivity status.

Treatment Allocation	Pf [1]	Pv [2]	Indeterminate [3]	Noninfected	Sporozoite Positivity Rate = $\dfrac{Pf + Pv}{Pf + Pv + unclear + uninfected} \times 100\%$
Baseline					
Active	12	9	0	4706	0.44%
Placebo	12	9	0	6244	0.34%
Intervention					
Active	3	8	0	8130	0.14%
Placebo	6	1	1	9615	0.07%

[1]Pf = *Plasmodium falciparum*
[2]Pv= *Plasmodium vivax*
[3]Indeterminate= *Plasmodium* positive sample but parasite species not identifiable.

Table 7. Intervention effect on parity and nulliparity rates (all anopheline species).[1]

	HLC Location[2]	Active (mean ± SD)	Placebo (mean ± SD)	% Change (95% CI) Active vs. Placebo
Parous	Indoor	0.41 ± 0.44	0.41 ± 0.45	-10.2 (-62.1, 113.2)
	Outdoor	0.40 ± 0.44	0.43 ± 0.45	-25.9 (-68.8, 75.6)
Nulliparous	Indoor	0.16 ± 0.29	0.12 ± 0.26	58.3 (-37.0, 298.0)
	Outdoor	0.17 ± 0.30	0.11 ± 0.25	54.9 (-37.6, 284.3)

[1] Mean and SD are descriptive statistics; % change was calculated from fitting negative binomial models.

[2] Position of Human Landing Catch (HLC) collector (indoor = near center of house; outdoor = on house verandah ~1m from edge of exterior wall.